Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Reuben

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Current Oncology Reports|May 25, 2016
Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted TherapySangeetha M Reddy, Alexandre Reuben, Jennifer A Wargo
European Journal of Immunology|March 20, 2014
The WT hemochromatosis protein HFE inhibits CD8⁺ T-lymphocyte activationAlexandre Reuben, Mikaël Phénix, Manuela M Santos, et al.
Frontiers in Immunology|May 22, 2018
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer TherapyMiles C Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, et al.
Immunity, Inflammation and Disease|May 6, 2017
The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune systemAlexandre Reuben, Jacqueline W Chung, Réjean Lapointe, et al.
Molecular Immunology|February 21, 2015
T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cellsAlexandre Reuben, Jessica Godin-Ethier, Manuela M Santos, et al.
Current Opinion in Immunology|May 31, 2016
Monitoring immune responses in the tumor microenvironmentJennifer A Wargo, Sangeetha M Reddy, Alexandre Reuben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?Alexandria P Cogdill, Peter A Prieto, Alexandre Reuben, et al.
Oncoimmunology|May 6, 2015
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanomaZachary A Cooper, Alexandre Reuben, Rodabe N Amaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2015
Does It MEK a Difference? Understanding Immune Effects of Targeted TherapyZachary A Cooper, Alexandre Reuben, Jacob Austin-Breneman, et al.
Cancer Immunology, Immunotherapy : CII|June 18, 2011
Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancerMarie-Andrée Forget, Alexandre Reuben, Simon Turcotte, et al.
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Current Oncology Reports|May 25, 2016
Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted TherapySangeetha M Reddy, Alexandre Reuben, Jennifer A Wargo
European Journal of Immunology|March 20, 2014
The WT hemochromatosis protein HFE inhibits CD8⁺ T-lymphocyte activationAlexandre Reuben, Mikaël Phénix, Manuela M Santos, et al.
Frontiers in Immunology|May 22, 2018
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer TherapyMiles C Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, et al.
Immunity, Inflammation and Disease|May 6, 2017
The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune systemAlexandre Reuben, Jacqueline W Chung, Réjean Lapointe, et al.
Molecular Immunology|February 21, 2015
T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cellsAlexandre Reuben, Jessica Godin-Ethier, Manuela M Santos, et al.
Current Opinion in Immunology|May 31, 2016
Monitoring immune responses in the tumor microenvironmentJennifer A Wargo, Sangeetha M Reddy, Alexandre Reuben, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?Alexandria P Cogdill, Peter A Prieto, Alexandre Reuben, et al.
Oncoimmunology|May 6, 2015
Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanomaZachary A Cooper, Alexandre Reuben, Rodabe N Amaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2015
Does It MEK a Difference? Understanding Immune Effects of Targeted TherapyZachary A Cooper, Alexandre Reuben, Jacob Austin-Breneman, et al.
Cancer Immunology, Immunotherapy : CII|June 18, 2011
Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancerMarie-Andrée Forget, Alexandre Reuben, Simon Turcotte, et al.
Pageof 14